You are here:

MS in the Media - 31 August 2018

Published on

25 - 31 August 2018

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Ibudilast slows atrophy in progressive MS

Ibudilast slowed loss of brain tissue (atrophy) by about half compared to placebo in a phase II study in people with primary or secondary progressive MS. The study wasn't looking at any effect on symptoms or on slowing progression and a future research will need to look at this

Source: National MS Society (USA)
Source: New Scientist

MS Trust link: Ibudilast

Sleep affects MS symptoms

Poor sleep is associated with reduced quality of life and greater fatigue, depression and anxiety according to a recent study

Source: MS News Today

MS Trust link: Sleep

Tecfidera and Gilenya compared

The effectiveness of Tecfidera or Gilenya was similar according to a real life study of people at two US clinics.  People on the treatments had fewer relapses than the rate seen in research trials.  More people chose to stop Tecfidera than Gilenya and tended to stop sooner.

Source: MS News Today

MS Trust link: MS Decisions - a guide to drugs for relapsing MS

Managing functional illness

A neurologist writes managing someone exhibiting symptoms of MS but whose tests indicate that they didn't have the condition.

Source: Daily Telegraph

Print this page